new report, page-25

Hi TJ,

In the past 48 hours there have been a number of reports around the globe. In a previous post I noted that its a Global Medical Arms Race for a herpes vaccine.

The National Institute of Allergy and Infectious Diseases Department (US) is now funding one groups trials. Another firm is moving closer to Phase III.

I continue to ponder what the share price of AHZ would be if it solely focused on it's core product - adapt whilst seeing a growing expense on the vaccine side. And vaccine research is phenomenally expensive.

http://www.nasdaq.com/article/genoc...data-for-genital-herpes-analyst-blog-cm400399

http://www.providencejournal.com/bu...-protect-against-genital-herpes-infection.ece

http://www.nasdaq.com/press-release/vical-granted-six-us-patents-for-hsv2-vaccines-20141008-00143